ES2032272T1 - Empleo de factor b inductor de cartilago (cif-b) para la elaboracion de medicamento para impedir el crecimiento tumoral. (reserva del art. 167.2 cpe). - Google Patents

Empleo de factor b inductor de cartilago (cif-b) para la elaboracion de medicamento para impedir el crecimiento tumoral. (reserva del art. 167.2 cpe).

Info

Publication number
ES2032272T1
ES2032272T1 ES198787309877T ES87309877T ES2032272T1 ES 2032272 T1 ES2032272 T1 ES 2032272T1 ES 198787309877 T ES198787309877 T ES 198787309877T ES 87309877 T ES87309877 T ES 87309877T ES 2032272 T1 ES2032272 T1 ES 2032272T1
Authority
ES
Spain
Prior art keywords
cif
activity
factor
cartilago
cpe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES198787309877T
Other languages
English (en)
Other versions
ES2032272T3 (es
Inventor
John M. Mcpherson
Daniel R. Twardzik
George J. Todaro
Karl A. Piez
Jane E. Ranchalis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Celtrix Pharmaceuticals Inc
Original Assignee
Oncogen LP
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP, Celtrix Pharmaceuticals Inc filed Critical Oncogen LP
Publication of ES2032272T1 publication Critical patent/ES2032272T1/es
Application granted granted Critical
Publication of ES2032272T3 publication Critical patent/ES2032272T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Abstract

UN POLIPEPTIDO LLAMADO FACTOR B INDUCTOR DE CARTILAGO (FIC-B) O FACTOR TRANSFORMADOR DEL CRECIMIENTO BETA 2 (FTC-BETA2) QUE SE ENCUENTRA EN LOS HUESOS Y QUE SE HA INDENTIFICADO HASTA AHORA POR TENER ACTIVIDAD INDUCTORA DE CARTILAGO IN VITRO, ACTIVIDAD FTC-BETA Y ACTIVIDAD ANTI-INFLAMATORIA, SE HA ENCONTRADO QUE POSEE ACTIVIDAD ONCOSTATICA EN TUMORES HUMANOS O ANIMALES, INCLUYENDO CARCINOMAS, ADENOCARCINOMAS, LINFOMAS Y MELANOMAS.
ES87309877T 1986-11-07 1987-11-06 Empleo de factor b inductor de cartilago (cif-b) para la elaboracion de medicamentos para impedir el crecimiento tumoral. Expired - Lifetime ES2032272T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/928,760 US4816442A (en) 1986-11-07 1986-11-07 Method of inhibiting tumor growth sensitive to CIF-βtreatment

Publications (2)

Publication Number Publication Date
ES2032272T1 true ES2032272T1 (es) 1993-02-01
ES2032272T3 ES2032272T3 (es) 1994-01-16

Family

ID=25456702

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87309877T Expired - Lifetime ES2032272T3 (es) 1986-11-07 1987-11-06 Empleo de factor b inductor de cartilago (cif-b) para la elaboracion de medicamentos para impedir el crecimiento tumoral.

Country Status (7)

Country Link
US (1) US4816442A (es)
EP (1) EP0271211B1 (es)
JP (1) JP2573259B2 (es)
AT (1) ATE79545T1 (es)
CA (1) CA1294874C (es)
DE (1) DE3781250T2 (es)
ES (1) ES2032272T3 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US5656587A (en) * 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US5104977A (en) * 1982-09-24 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Purified transforming growth factor beta
US6586394B1 (en) 1985-04-19 2003-07-01 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitor
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5221734A (en) * 1987-10-01 1993-06-22 Ciba-Geigy Corporation Process for preparing a polypeptide growth factor for milk
KR900700116A (ko) * 1988-04-06 1990-08-11 원본미기재 뼈-유도 단백질
US5268455A (en) * 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
EP0489062A4 (en) * 1989-08-21 1992-08-12 Celtrix Laboratories, Inc. Bone-specific protein
IL95500A (en) * 1989-09-11 1997-03-18 Matrix Pharma ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
US5888720A (en) * 1992-10-27 1999-03-30 Yissum Research And Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs
US5531791A (en) * 1993-07-23 1996-07-02 Bioscience Consultants Composition for repair of defects in osseous tissues, method of making, and prosthesis
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
RU2217196C2 (ru) 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
WO2005059133A2 (en) * 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
TWI299257B (en) * 2005-05-16 2008-08-01 Tung Hai Biotechnology Corp γ-POLYGLUTAMIC ACID (γ-PGA, H FORM), γ-POLYGLUTAMATES AND γ-POLYGLUTAMATE HYDROGEL FOR USE AS NUTRITION SUPPLEMENTS IN DIETARY PRODUCTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (en) * 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
WO1984004924A1 (en) * 1983-06-03 1984-12-20 Us Commerce Purified transforming growth factor-beta derived from human platelets and placentas
EP0169016B2 (en) * 1984-07-16 2004-04-28 Celtrix Pharmaceuticals, Inc. Polypeptide cartilage-inducing factors found in bone
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation

Also Published As

Publication number Publication date
ATE79545T1 (de) 1992-09-15
CA1294874C (en) 1992-01-28
DE3781250D1 (de) 1992-09-24
EP0271211B1 (en) 1992-08-19
ES2032272T3 (es) 1994-01-16
US4816442A (en) 1989-03-28
EP0271211A2 (en) 1988-06-15
DE3781250T2 (de) 1992-12-17
AU591358B2 (en) 1989-11-30
JPS63211236A (ja) 1988-09-02
AU8067987A (en) 1988-05-12
JP2573259B2 (ja) 1997-01-22
EP0271211A3 (en) 1989-10-18

Similar Documents

Publication Publication Date Title
ES2032272T1 (es) Empleo de factor b inductor de cartilago (cif-b) para la elaboracion de medicamento para impedir el crecimiento tumoral. (reserva del art. 167.2 cpe).
GR3004229T3 (es)
ATE69376T1 (de) Haarwuchsmittel.
MX163401B (es) Un procedimiento para preparar pseudomonato calcico cristalino o un hidrato del mismo
ES2101106T3 (es) Metodo para estimular la respuesta inmunitaria.
EP0190018A3 (en) Use of transforming growth factor to promote wound healing and composition therefor
IL79403A0 (en) Production of dry,bioactive recombinant growth hormones
DE59409604D1 (de) Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
EP0253146A3 (en) The use of d-fenfluramine for the manufacture of medicaments for treating depression
ZA904353B (en) Use of a polypeptide having the activity of human interleukin 2 for preparing a pharmaceutical composition intended for the treatment of primary cancers of the pleura
SE8802805L (sv) Farmaceutisk komposition foer att underlaetta saarlaekning och foerfarande foer framstaellning av densamma
DE3766885D1 (en) Chlorpheniramine therapie.
IL83956A (en) Compositions for promoting wound healing containing a serotonin-antagonist
ES2039276T3 (es) Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.
ZA9010409B (en) Utilisation of a polypeptide with human 2 interleukine activity in the preparation of a pharmaceutical composition for the treatment of epithelial malignant tumours
IE883116L (en) Preparation of antiviral and antitumour pharmaceutical and¹veterinary composition
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
ATE73664T1 (de) Arzneimittel zur regulierung der hormonellen sekretionen und zur behandlung der weiblichen sterilitaet.
ES542223A0 (es) Un procedimiento para la preparacion de un producto trans- formador de la estructura del yeso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 271211

Country of ref document: ES